Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Conditional restriction
WADA 2026: S6.B, specified, prohibited in competition above a urine concentration of 5 micrograms/mL. The future 2027 List retains this rule. See the separate S5 combination condition. [1] [2]
2026 and 2027 List, S6.B, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Threshold and combination conditions
When a prohibited diuretic or masking agent is detected with formoterol, salbutamol, cathine, ephedrine, methylephedrine or pseudoephedrine, S5 has an additional TUE requirement even below the usual threshold. The note expressly excludes qualifying carbonic-anhydrase-inhibitor eye administration and local dental felypressin. It is not a dosing or test-clearance rule. [1] [2]
- A urine threshold cannot be converted into a safe dose or a guaranteed test result.
Identity matters
The cathine footnote covers d-norpseudoephedrine and its l-isomer. Its threshold is not the rule for cathinone or all other similarly named compounds. [1] [2]
Plant exposure
DEA and EUDA identify cathine and cathinone as active constituents of khat. That supports a specific botanical exposure; it does not extend cathine’s threshold to cathinone. [3] [4]
- The sources do not establish a universal legal status or safety profile for every khat product.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16 · S5 p.12
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16 · S5 p.12
- E10. DEA. Khat fact sheet; EUDA. Khat drug profile. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Khat composition · Khat composition; WADA S6 family entry
- E10. DEA. Khat fact sheet; EUDA. Khat drug profile. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Khat composition · Khat composition; WADA S6 family entry
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.